Research, Takeda Pharmaceutical Company, Fujisawa, Kanagawa, Japan.
Research, Takeda Pharmaceutical Company, Fujisawa, Kanagawa, Japan.
Biochem Biophys Res Commun. 2023 Oct 8;676:6-12. doi: 10.1016/j.bbrc.2023.07.028. Epub 2023 Jul 17.
Phenotypic screening is gaining attention as a powerful method for identifying compounds that regulate cellular phenotypes of interest through novel mechanisms of action. Recently, a new modality of compounds, called molecular glues, which can induce the degradation of target proteins by forming ternary complexes of E3 ligases, has emerged from phenotypic screening. In this study, using global proteomic analysis, we identified a novel Cyclin K degrader, T4, which was previously discovered through phenotypic screening for alternative polyadenylation regulation. Our detailed mechanistic analysis revealed that T4 induced Cyclin K degradation, leading to the regulation of alternative polyadenylation. Additionally, we generated a more potent Cyclin K degrader, TR-213, through a structure-activity relationship study of T4. T4 and TR-213 are structurally distinct from other Cyclin K degraders and can be used as novel chemical tools to further analyze the degradation of Cyclin K and the regulation of alternative polyadenylation.
表型筛选作为一种强大的方法,正在受到关注,它可以通过新颖的作用机制来识别调节感兴趣的细胞表型的化合物。最近,一种新的化合物模式,称为分子胶水,通过形成 E3 连接酶的三元复合物,可以诱导靶蛋白的降解,这种化合物是从表型筛选中出现的。在这项研究中,我们使用全蛋白质组学分析,鉴定了一种新的细胞周期蛋白 K 降解剂 T4,它是通过对可变多聚腺苷酸化调节的表型筛选而发现的。我们详细的机制分析表明,T4 诱导细胞周期蛋白 K 降解,从而调节可变多聚腺苷酸化。此外,我们通过对 T4 的结构-活性关系研究,生成了一种更有效的细胞周期蛋白 K 降解剂 TR-213。T4 和 TR-213 在结构上与其他细胞周期蛋白 K 降解剂不同,可以作为新的化学工具,进一步分析细胞周期蛋白 K 的降解和可变多聚腺苷酸化的调节。